ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology logoZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ZIOP
  • CUSIP: 98973P10
  • Web: www.ziopharm.com
Capitalization:
  • Market Cap: $767.21 million
  • Outstanding Shares: 130,701,000
Average Prices:
  • 50 Day Moving Avg: $5.92
  • 200 Day Moving Avg: $6.34
  • 52 Week Range: $4.45 - $7.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.17
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.49 million
  • Price / Sales: 118.21
  • Book Value: ($0.73) per share
  • Price / Book: -8.04
Profitability:
  • EBIDTA: ($166,930,000.00)
  • Net Margins: -2,600.79%
  • Return on Assets: -44.55%
Debt:
  • Current Ratio: 5.31%
  • Quick Ratio: 5.31%
Misc:
  • Average Volume: 1.32 million shs.
  • Beta: 1.68
  • Short Ratio: 23.66
 
Frequently Asked Questions for ZIOPHARM Oncology (NASDAQ:ZIOP)

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) released its quarterly earnings results on Monday, May, 1st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.03. The firm had revenue of $1.60 million for the quarter, compared to analysts' expectations of $1.71 million. The firm's quarterly revenue was down 18.8% on a year-over-year basis. View ZIOPHARM Oncology's Earnings History.

Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?

4 equities research analysts have issued 1-year price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $9.50 to $23.00. On average, they expect ZIOPHARM Oncology's share price to reach $16.25 in the next year. View Analyst Ratings for ZIOPHARM Oncology.

Are investors shorting ZIOPHARM Oncology?

ZIOPHARM Oncology saw a increase in short interest in June. As of June 30th, there was short interest totalling 36,003,899 shares, an increase of 0.5% from the June 15th total of 35,809,383 shares. Based on an average daily trading volume, of 1,370,404 shares, the days-to-cover ratio is presently 26.3 days. Currently, 28.2% of the company's stock are sold short.

Who are some of ZIOPHARM Oncology's key competitors?

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the folowing people:

  • Laurence James Neil Cooper M.D., Ph.D., Chief Executive Officer
  • Kevin G. Lafond CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Caesar J. Belbel, Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
  • Murray Brennan, Non-Executive Lead Independent Director
  • Randal J. Kirk, Director
  • James A. Cannon, Independent Director
  • Wyche Fowler Jr., J.D, Independent Director
  • Timothy McInerney, Independent Director

Who owns ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Creative Planning (0.05%) and Dixon Hubard Feinour & Brown Inc. VA (0.02%). View Institutional Ownership Trends for ZIOPHARM Oncology.

Who bought ZIOPHARM Oncology stock? Who is buying ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning. View Insider Buying and Selling for ZIOPHARM Oncology.

How do I buy ZIOPHARM Oncology stock?

Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOPHARM Oncology stock can currently be purchased for approximately $5.87.


MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ZIOPHARM Oncology (NASDAQ:ZIOP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $16.25 (176.83% upside)

Analysts' Ratings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/1/2017HC WainwrightInitiated CoverageBuy -> Buy$9.50HighView Rating Details
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/AView Rating Details
1/12/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
8/10/2016Wells Fargo & CompanyUpgradeUnderperform -> Market PerformN/AView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00N/AView Rating Details
6/2/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Earnings by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Earnings History by Quarter for ZIOPHARM Oncology (NASDAQ ZIOP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.12)($0.15)$1.71 million$1.60 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)$1.82 million$1.92 millionViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)$57.70 million$0.27 millionViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$0.20 million$0.63 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ZIOPHARM Oncology (NASDAQ:ZIOP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 38.05%
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ZIOPHARM Oncology (NASDAQ:ZIOP)
Latest Headlines for ZIOPHARM Oncology (NASDAQ:ZIOP)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Expect ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 24 at 11:06 AM
feeds.benzinga.com logoZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET
feeds.benzinga.com - July 24 at 7:38 AM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 17 at 11:29 AM
zacks.com logoPfizer's Mylotarg Recommended by FDA Advisory Committee
www.zacks.com - July 13 at 11:31 AM
globenewswire.com logoZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + ... - GlobeNewswire (press release)
globenewswire.com - June 30 at 2:34 AM
americanbankingnews.com logo Analysts Anticipate ZIOPHARM Oncology Inc (ZIOP) Will Post Quarterly Sales of $1.59 Million
www.americanbankingnews.com - June 29 at 9:16 AM
streetinsider.com logoZiopharm Oncology (ZIOP) Reports Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
www.streetinsider.com - June 29 at 8:15 AM
americanbankingnews.com logoZacks: Brokerages Anticipate ZIOPHARM Oncology Inc (ZIOP) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - June 27 at 10:22 PM
seekingalpha.com logoBullish On Ziopharm
seekingalpha.com - June 22 at 2:54 PM
feeds.benzinga.com logoMid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge
feeds.benzinga.com - June 20 at 3:55 PM
americanbankingnews.com logoZIOPHARM Oncology Inc (ZIOP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 20 at 10:00 AM
finance.yahoo.com logoETFs with exposure to ZIOPHARM Oncology, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 4:18 PM
seekingalpha.com logoZIOPHARM Oncology (ZIOP) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 12 at 3:15 PM
streetinsider.com logoZiopharm Oncology (ZIOP) Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at ASCO
www.streetinsider.com - June 6 at 3:16 AM
americanbankingnews.com logo$1.59 Million in Sales Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - June 3 at 7:53 AM
globenewswire.com logoZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 2 at 8:17 AM
americanbankingnews.com logo Analysts Anticipate ZIOPHARM Oncology Inc. (ZIOP) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - June 1 at 6:28 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - June 1 at 11:46 AM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 26 at 10:14 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : May 26, 2017
finance.yahoo.com - May 26 at 9:15 AM
reuters.com logoBRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology
www.reuters.com - May 22 at 7:48 PM
globenewswire.com logoZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 8:21 AM
streetinsider.com logoZiopharm Oncology (ZIOP) Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at ASCO
www.streetinsider.com - May 17 at 11:38 PM
finance.yahoo.com logoETFs with exposure to ZIOPHARM Oncology, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 7:54 PM
nasdaq.com logoZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock - Nasdaq
www.nasdaq.com - May 12 at 3:15 PM
finance.yahoo.com logoZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock
finance.yahoo.com - May 12 at 3:15 PM
finance.yahoo.com logoZiopharm Oncology's stock tumbles after stock offering prices at deep discount
finance.yahoo.com - May 12 at 3:15 PM
finance.yahoo.com logoZiopharm Prices Secondary Offering
finance.yahoo.com - May 12 at 3:15 PM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : May 9, 2017
finance.yahoo.com - May 9 at 8:49 PM
americanbankingnews.com logoZacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 EPS
www.americanbankingnews.com - May 8 at 2:24 PM
americanbankingnews.com logoGriffin Securities Weighs in on ZIOPHARM Oncology Inc.'s Q2 2017 Earnings (ZIOP)
www.americanbankingnews.com - May 8 at 7:11 AM
finance.yahoo.com logoETFs with exposure to ZIOPHARM Oncology, Inc. : May 4, 2017
finance.yahoo.com - May 5 at 5:40 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 7:07 PM
reuters.com logoBRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
www.reuters.com - May 3 at 9:32 AM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Receives Daily Media Sentiment Score of 0.11
www.americanbankingnews.com - May 2 at 10:38 AM
finance.yahoo.com logoEdited Transcript of ZIOP earnings conference call or presentation 1-May-17 8:30pm GMT - Yahoo Finance
finance.yahoo.com - May 2 at 8:03 AM
finance.yahoo.com logoZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities - Yahoo Finance
finance.yahoo.com - May 2 at 8:03 AM
finance.yahoo.com logoEdited Transcript of ZIOP earnings conference call or presentation 1-May-17 8:30pm GMT
finance.yahoo.com - May 2 at 8:03 AM
finance.yahoo.com logoZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia
finance.yahoo.com - May 2 at 8:03 AM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 1 at 11:40 PM
finance.yahoo.com logoInvestor Network: ZIOPHARM Oncology, Inc. to Host Earnings Call
finance.yahoo.com - May 1 at 7:51 PM
marketbeat.com logoZiopharm reports 1Q loss
marketbeat.com - May 1 at 4:33 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 1 at 1:34 PM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 29 at 9:16 AM
globenewswire.com logoZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1 ... - GlobeNewswire (press release)
globenewswire.com - April 26 at 5:27 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 26 at 4:36 PM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Given News Sentiment Rating of 0.30
www.americanbankingnews.com - April 26 at 8:13 AM
finance.yahoo.com logoZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1 ... - Yahoo Finance
finance.yahoo.com - April 24 at 8:16 AM
feeds.benzinga.com logoZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET
feeds.benzinga.com - April 24 at 7:19 AM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Given News Impact Score of -0.06
www.americanbankingnews.com - April 23 at 11:49 AM

Social

Chart

ZIOPHARM Oncology (ZIOP) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff